Expert Views from Pharma and Biotech Industry Leaders
Refine Search
Pharmaceutical
An exclusive Expert View column written for The Pharma Letter by Thomas Cueni, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) director general and co-chair of the APEC Biopharmaceutical Working Group on Ethics. 6 December 2018
Biotechnology
Charlotte Tillett, partner, and Emily Hocken, trainee, at Stevens & Bolton, offer an Expert View on the significance of the UK Supreme Court ruling in Warner-Lambert (WL) v Generics relating to WL’s best-selling pain relief drug, Lyrica (pregabalin). 28 November 2018
Biotechnology
Just over 140 years ago, the world’s first industrial-sized research and development laboratory opened. As someone who’s devoted his working life to finding new research and development (R&D) breakthroughs, I’m envious of the explosion of activity that made the lab’s owner, Thomas Edison, one of history’s most remarkable inventors. But it’s his process of innovation that inspires me, as much as his life-changing creations. 27 November 2018
Pharmaceutical
The success of any pre-clinical research program relies on selecting the right animal for a study, writes Emmanuel Gomas, European services manager at Envigo, in an expert view piece. 21 November 2018
Biotechnology
In an Expert View column, Stephen Bennett (pictured) and Mary Foord-Weston, from UK-based law firm Hogan Lovells, consider the questions that new oncology treatments raise around the current intellectual property (IP) system. 16 November 2018
Biosimilars
Jean-Yves Brault, UK country manager for Mylan, considers the much-needed copies of biologics that are now coming to the fore. 12 November 2018
Pharmaceutical
Drug companies, which have learned to live with advertisements calling out a litany of possible side effects for their drugs, may want to take a couple of aspirin. That’s because the Department of Health and Human Services recently announced a new proposed rule by the Centers for Medicare and Medicaid Services that would require them to disclose the list price — more precisely, the wholesale acquisition cost — of medications they sell in direct-to-consumer television ads. 7 November 2018
Pharmaceutical
In an Expert View column, Helen Westropp, managing partner of branding agency Coley Porter Bell, describes how tens of millions of dollars are wasted in M&A deals every year when acquirers fail to understand the value in the brand and culture of the business they are buying. This is particularly the case in pharma and biotech businesses. 5 November 2018
Pharmaceutical
Kerry Garcia and Nyasha Gardner, UK-based immigration specialists at law firm Stevens & Bolton, provide an Expert View what the recently published Migration Advisory Committee (MAC) report on immigration means for businesses in the life sciences sector. 25 October 2018
Biotechnology
Intrathecal catheterization is a highly effective delivery method for drugs targeting neurological diseases, writes Brad Gien, head of surgery, North America, Envigo, in an Expert View piece. 17 October 2018
Biotechnology
Initial public offerings (IPOs) are often seen as attractive by business owners in the life sciences or biotech field, writes Alan Wovsaniker, a partner with Lowenstein Sandler, in an Expert View column on the topic. 11 October 2018
Biosimilars
Kevin Noonan, a partner with McDonnell Boehnen Hulbert & Berghoff, provides commentary on the US Food and Drug Administration's Biosimilars Action Plan in an Expert View piece. 4 October 2018
Biotechnology
In an expert view, Maggie Chang, vice president, regulatory affairs, at China-based Hangzhou Tigermed Consulting, takes a look at what is now happening in China’s amended new drug approval system. 28 September 2018
Biotechnology
With CAR-T therapies closer than ever to delivering on their promise but still facing significant obstacles, Eva Marchese and Cécile Matthews from Charles River Associates provide an Expert View on the topic. 24 September 2018
Pharmaceutical
Supply chain imperatives are evolving from drug production and delivery that are limited in scope towards a versatile supply chain addressing the needs of multiple stakeholders (such as caregivers, patients and insurance companies). The traditional supply chain approach based on materials requirement planning has progressed to its limits. 17 September 2018
Pharmaceutical
In the first half of 2018, global equity markets experienced volatility. But, emerging markets, such as India and China, displayed a healthy resilience, even outperforming their developed counterparts. 11 September 2018
Pharmaceutical
In an Expert View piece, Iain Barton, healthcare strategy executive at supply chain management company Imperial Logistics, considers the danger posed by fake and sub-standard medicines and what needs to be done about the issue. 7 September 2018
Pharmaceutical
In an Expert View piece, Elisabethann Wright and Jane Summerfield, from law firm Hogan Lovells, look at some useful points to come out of the UK government regarding the implications of a ‘hard Brexit’. 31 August 2018
Pharmaceutical
In light of a report on the 10 most important medicines over the life of the UK's National Health Service (NHS), the Association of the British Pharmaceutical Industry's (ABPI) deputy chief scientific officer, Sheuli Porkess, outlines how pharma's process of taking a substance from molecule to medicine requires persistence. 24 August 2018
Biotechnology
In an Expert View piece, Charlie Johnson, chief executive of UK biotech ADC Bio, takes a look at a product class that is still in its infancy. 16 August 2018
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
An Expert View from Leslie Orne, president and chief executive, Trinity Life Sciences. 20 September 2024
Pharmaceutical
An Expert View from Vikas Krishan, chief digital business officer at Altimetrik. 4 September 2024
Pharmaceutical
An Expert View from the new chief executive of Gavi, the Vaccine Alliance, Sania Nishtar. 13 August 2024
Pharmaceutical
The biopharmaceutical supply chain plays a pivotal role in ensuring the seamless delivery of therapeutics to patients. However, pharmaceutical supply chains face several challenges, including regulatory complexities, global competition, and the need for innovation. 26 July 2024
Pharmaceutical
An Expert View from William Hind of Alpharmaxim and Lisa Campbell of SSI Strategy. 18 July 2024
Pharmaceutical
An Expert View from Brendan Frey, founder and chief innovation officer of Deep Genomics. 4 July 2024
Pharmaceutical
A recent survey from IDC highlights that 49% of the pharmaceutical industry believes they have achieved success in implementing artificial intelligence (AI) across the entire pharmacovigilance (PV) value chain. However, over the next two years, the industry expects this number to only marginally shift to just 51%. 17 June 2024
Biotechnology
An Expert View from Danie du Plessis, executive vice president, pharmaceutical operations at Kyowa Kirin International, and chair of the Medical Affairs Professional Society (MAPS) board. 29 May 2024
Pharmaceutical
The use of AI across all industries and sectors has been heralded as driving efficiency and accelerating innovation, with some experts even citing the technology as the biggest disruptor of our lifetime. 21 May 2024
Expert View
In an Expert View column, Bruce Leuchter, chief executive of Neurvati Neurosciences, a Blackstone Life Sciences portfolio company, outlines the importance of increased investment in research and development and innovative business models, to bring more therapies for neurological disorders to patients. 17 May 2024
Biotechnology
A new age of innovation in immunology could change medical practice and people’s lives, as long as all parts of the system learn, evolve and work together, writes Anant Murthy, General Manager, argenx EMEA, in an Expert View piece. 1 May 2024
Pharmaceutical
An Expert View from Adrienne Rivlin, a partner in LEK’s Healthcare practice. 19 April 2024
Pharmaceutical
A second Expert View piece from Xandra Neuberger, associate director, regulatory affairs and international service lead for clinical trial applications at PharmaLex. 4 April 2024
Biotechnology
An Expert View from Tomislav Kamenski, Senior Director, Therapy Area Market Access Leader, Hematology, Johnson & Johnson. 25 March 2024
Pharmaceutical
An Expert View from Rajan Jethwa, chief executive of Ellipses Pharma. 24 March 2024
Pharmaceutical
Xandra Neuberger, associate director, regulatory affairs and international service lead for clinical trial applications at PharmaLex, provides an Expert View. 29 February 2024
Pharmaceutical
In an Expert View piece, Mark Seymour, Director and Head of Media, Healthcare, at FleishmanHillard London, argues that in the ever-evolving world of healthcare, the rules of communications have not changed, they have just become more intricate, demanding a renewed focus on the essentials. 8 February 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze